- Total planned investment is around 500 million USD over five years to 
      raise manufacturing capacity 
    - Continues long-term strategy of increasing capacity to respond to  
      growing industry demand and new market opportunities 
    - Cytiva hiring nearly 1,000 personnel in Austria, China, Singapore, 
      Sweden, Switzerland, and the United States 
    - New manufacturing lines, 24/7 shift patterns, and increased automation 
      will deliver additional manufacturing capacity

Cytiva, a global life sciences leader, is expanding its manufacturing capacity 
and hiring personnel in key areas to support the long-term growth of the 
biotechnology industry. 

Photo - https://mma.prnewswire.com/media/1252653/Cytiva_Capacity_Expansion.jpg

Logo - https://mma.prnewswire.com/media/1138636/cytiva_Logo.jpg 

Emmanuel Ligner, President and CEO, Cytiva, says: "We know from our customers 
that availability and lead time are the most important considerations after 
quality. Cytiva's long-term commitment is to deliver the best product, at the 
right time, and support our customers with expertise.  The industry is growing 
rapidly, now even more due to COVID-19. Accelerating this investment will 
reinforce these commitments."

While the COVID-19 pandemic is increasing short-term demand, the 
biotherapeutics industry was already predicted to grow by double digits between 
now and 2025[1].  Cytiva's global product manufacturing and distribution 
network encompasses 13 sites across Asia, the Americas, and Europe. The 
investments, totaling around 500 million USD, will respond to in-region, 
for-region demand, bolster security of supply through dual manufacturing, and 
increase overall global capacity in key product areas.  

Cytiva is investing in talent, too, hiring nearly 1,000 people around the 
world. Ligner says: "We're acquiring talent in every area of our business, from 
commercial to those on production lines, in order to better serve customers for 
the long term." 

Single-use technologies are used to manufacture 85%[2] of the biologics 
currently in pre-commercial and clinical manufacturing lines. As regulatory 
approvals occur, demand for single-use products at manufacturing scale is 
expected to grow substantially. Through additional equipment and infrastructure 
at multiple sites, Cytiva's capacity to manufacture single-use products will 
more than double.

In Asia-Pacific, single-use capacity will triple through a partnership with one 
of the largest healthcare technology suppliers in China, Wego, which is already 
producing consumables for Cytiva's customers in the region.  

Cell culture media production will increase thanks to new manufacturing lines 
and cleanroom space in Logan, Utah, as well as additional shifts and personnel. 
The Singapore and Pasching, Austria locations are increasing output through 
more personnel and additional work shifts. This follows on from a tenfold 
increase in powdered cell culture media production announced in May 2018.

The manufacturing capacity of Cytiva's MabSelect and Capto chromatography 
product platforms has doubled, as part of a 70 million USD per year (2017 - 
2022) capacity gains and facility modernization program at its Uppsala, Sweden 
site. Now, the plant is fully automated with the latest technology to allow 
continuous manufacturing. Other elements include the capacity extension of the 
Sephadex resin, setting-up additional facilities for in-house manufacturing, 
and the development of automation and digitalization infrastructure. 

Cytiva is also enabling the rapidly growing cell and gene therapy market 
through an investment in a new facility in Grens, Switzerland to manufacture 
single-use kits for its Sepax and Sefia cell processing systems.

Cytiva has a longstanding and comprehensive Security of Supply program in place 
which enables manufacturing output to respond to market demands while ensuring 
that operations and service capabilities continue safely. For some product 
lines, part of the solution is having multiple sites able to deliver to 
customers.  

Ligner says: "Dual manufacturing assures our customers that if one location 
encounters capacity constraints, we have plenty of back-up ready to activate."

About Cytiva 
Cytiva is a global life sciences leader with over 7,000 associates across 40 
countries dedicated to advancing and accelerating therapeutics. As a trusted 
partner to customers that range in scale and scope, Cytiva brings speed, 
efficiency, and capacity to research and manufacturing workflows, enabling the 
development, manufacture, and delivery of transformative medicines to patients.

[1] BioPlan's 2020 Report and Survey of Biopharmaceutical Manufacturing 
    Capacity and Production, p 29 
[2] BioPlan's 2020 Report and Survey of Biopharmaceutical Manufacturing 
    Capacity and Production, p 58

SOURCE: Cytiva

Media Contact: Dodi Axelson 
               Dodi.axelson@cytiva.com
               +46730958191